Sei Investments Co. Buys Shares of 52,748 Century Therapeutics, Inc. (NASDAQ:IPSC)

Sei Investments Co. purchased a new position in shares of Century Therapeutics, Inc. (NASDAQ:IPSC) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 52,748 shares of the company’s stock, valued at approximately $53,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in IPSC. Geode Capital Management LLC increased its stake in Century Therapeutics by 3.5% in the 3rd quarter. Geode Capital Management LLC now owns 968,182 shares of the company’s stock valued at $1,656,000 after buying an additional 32,614 shares during the last quarter. State Street Corp boosted its stake in shares of Century Therapeutics by 7.4% during the 3rd quarter. State Street Corp now owns 836,914 shares of the company’s stock worth $1,431,000 after buying an additional 57,323 shares during the last quarter. Wellington Management Group LLP bought a new position in shares of Century Therapeutics in the 3rd quarter valued at about $284,000. JPMorgan Chase & Co. increased its position in shares of Century Therapeutics by 257.6% in the third quarter. JPMorgan Chase & Co. now owns 71,721 shares of the company’s stock valued at $123,000 after acquiring an additional 51,664 shares during the last quarter. Finally, Barclays PLC raised its holdings in Century Therapeutics by 283.6% during the third quarter. Barclays PLC now owns 61,945 shares of the company’s stock worth $106,000 after acquiring an additional 45,797 shares in the last quarter. 50.20% of the stock is currently owned by institutional investors and hedge funds.

Century Therapeutics Stock Up 17.7 %

IPSC opened at $0.48 on Friday. Century Therapeutics, Inc. has a 12-month low of $0.34 and a 12-month high of $4.07. The business has a 50 day moving average of $0.60 and a 200-day moving average of $1.03. The stock has a market cap of $41.30 million, a price-to-earnings ratio of -0.26 and a beta of 1.83.

Century Therapeutics (NASDAQ:IPSC) last released its quarterly earnings data on Wednesday, March 19th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.02. The firm had revenue of $4.18 million for the quarter, compared to the consensus estimate of $0.67 million. Century Therapeutics had a negative net margin of 4,837.73% and a negative return on equity of 61.66%. As a group, analysts expect that Century Therapeutics, Inc. will post -1.61 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on IPSC. Piper Sandler decreased their price target on Century Therapeutics from $4.00 to $2.00 and set an “overweight” rating for the company in a research note on Thursday, March 20th. Guggenheim reissued a “buy” rating on shares of Century Therapeutics in a report on Friday, March 28th. Chardan Capital lowered their target price on shares of Century Therapeutics from $11.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, March 24th. Finally, HC Wainwright cut their price target on shares of Century Therapeutics from $5.00 to $2.00 and set a “buy” rating for the company in a research note on Thursday, April 3rd. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $4.40.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.